Impact of Trump's Drug Price Reduction Plan on Indian Pharmaceutical Companies

2. Cipla Limited

U.S. Sales (Q2 FY24): $229 million Cipla has expanded rapidly in the U.S. through strategic acquisitions like InvaGen and successful respiratory and oncology launches. It also has a strong pipeline of complex generics and 505(b)(2) opportunities. CMP: 1505 Nearest Support: 1425 The stock could face temporary weakness as margins in the U.S. market compress. However, its innovation-led pipeline provides a cushion against prolonged downside. 3. Lupin Limited U.S. Sales (Q2 FY24): $229 million Lupin holds a strong presence in cardiovascular, diabetes, and CNS therapies. It ranks among the top three for market share in 57 U.S. products. Regulatory headwinds have slowed recent launches. CMP: 2015 Nearest Support: 1880 Lupin could experience pricing headwinds but may stabilize if new complex generics gain faster approval or if regulatory risks ease. Potential Impact on Indian Pharma Companies 1. Revenue and Margin Pressure The MFN pricing model directly impacts profitability. Indian pharma companies, already operating on thin margins in generics, may face additional compression if forced to reduce prices to match global benchmarks. This could delay new product rollouts and limit reinvestment in innovation. 2. Regulatory Uncertainty and Pipeline Disruption The MFN rule may alter the economic viability of complex generics and biosimilar launches in the U.S. For companies heavily invested in U.S. approvals, shifting regulatory conditions could disrupt launch schedules, reduce expected returns, and increase go-to-market risk. this is part 2 in continuation conclusion in next part keep reading